Trelegy Ellipta is a once-daily inhaler prescribed for two chronic lung conditions: COPD (chronic obstructive pulmonary disease) and asthma in adults. It combines three medications into a single device, replacing what previously required two or even three separate inhalers. It is a maintenance treatment, meaning you use it every day to control symptoms over time, not during a sudden breathing emergency.
The Two Conditions Trelegy Treats
The FDA has approved Trelegy for the maintenance treatment of COPD and for asthma in patients 18 and older. In both cases, it’s typically prescribed when simpler, one- or two-drug inhalers aren’t controlling symptoms well enough. If you’re already on a dual-combination inhaler and still experiencing flare-ups, shortness of breath, or nighttime symptoms, Trelegy is often the next step up.
For COPD, that includes people with chronic bronchitis, emphysema, or both. For asthma, it’s reserved for adults whose disease remains inadequately controlled on other therapies. It is not approved for children.
How the Three Ingredients Work Together
Trelegy contains three active drugs, each targeting a different aspect of breathing difficulty:
- Fluticasone furoate is an inhaled corticosteroid that reduces inflammation in the airways. Swollen, inflamed airways are a core problem in both COPD and asthma, and this ingredient works to calm that response over time.
- Umeclidinium is a long-acting anticholinergic. It blocks signals that cause the muscles around your airways to tighten, helping them stay relaxed and open for a full 24 hours.
- Vilanterol is a long-acting bronchodilator that also relaxes airway muscles, but through a different pathway than umeclidinium. Having two bronchodilators that work through separate mechanisms produces a stronger effect than either one alone.
The combination tackles airway inflammation, muscle tightening, and restricted airflow simultaneously. That three-pronged approach is why it’s called “triple therapy.”
What the Clinical Evidence Shows for COPD
In large trials involving thousands of COPD patients, Trelegy reduced flare-ups (exacerbations) significantly compared to two-drug inhalers. Patients on Trelegy had a 25% lower annual rate of moderate or severe exacerbations compared to those using a bronchodilator-only dual inhaler, and a 15% lower rate compared to a steroid-plus-bronchodilator combination. Those reductions matter because each COPD flare-up can mean days of worsened breathing, courses of oral steroids or antibiotics, and sometimes hospitalization.
Lung function also improved. Patients on Trelegy gained roughly 97 milliliters more air volume on their standard breathing test compared to those on a steroid-plus-bronchodilator dual inhaler, and 54 milliliters more compared to a two-bronchodilator combination. While those numbers sound small, in a disease where lung capacity steadily declines, even modest gains translate to noticeably easier breathing during daily activities like walking up stairs or carrying groceries.
How Trelegy Helps With Asthma
For asthma, Trelegy is aimed at adults whose symptoms aren’t adequately managed by a two-drug inhaler containing a steroid and a long-acting bronchodilator. Adding the anticholinergic component (umeclidinium) provides additional airway opening on top of what the other two drugs achieve. Clinical trials measured improvements in lung function at 24 weeks, and the addition of that third drug produced meaningful gains in airflow for people who had already plateaued on dual therapy.
If you have severe asthma, your prescriber may choose a higher-strength version of Trelegy with double the steroid dose to better control inflammation.
Two Dosage Strengths
Trelegy comes in two strengths. The standard version (100/62.5/25 mcg) is used for both COPD and asthma. A higher-strength version (200/62.5/25 mcg) is available only for asthma patients who need more anti-inflammatory power. The difference is entirely in the steroid component; the other two ingredients stay the same.
Both strengths are taken as one inhalation, once a day, at the same time each day. That simplicity is one of the biggest practical advantages. Managing multiple inhalers on different schedules is a common reason people miss doses, and consolidating everything into one device once daily improves the odds of consistent use.
How Quickly It Works
Some airway opening can begin within hours of your first dose, but Trelegy is not a fast-acting treatment. The full benefit, particularly the anti-inflammatory effect, builds over days to weeks of consistent daily use. Most people notice meaningful improvement in their day-to-day breathing within the first few weeks.
This is an important distinction: Trelegy is not a rescue inhaler. It will not help during a sudden asthma attack or an acute episode of COPD breathlessness. You still need a separate short-acting rescue inhaler (like albuterol) for those situations. Trelegy’s role is to reduce how often those emergencies happen in the first place.
Common Side Effects
The most frequently reported side effects in clinical trials were upper respiratory infections (nose and throat infections), throat inflammation, and headache. These each affected up to 1 in 10 users. Pneumonia is a more serious but less common risk, particularly in COPD patients, and is a known concern with any inhaled steroid.
To reduce the chance of developing mouth or throat soreness (a common side effect of the steroid component), you should rinse your mouth with water after each use and spit it out rather than swallowing. This simple step washes away steroid residue that can otherwise encourage fungal growth in the mouth, a condition called oral thrush.
Who Should Not Use Trelegy
Trelegy is not appropriate for anyone with a severe allergy to milk proteins, because the powder formulation contains lactose derived from milk. It’s also not for people who have had a serious allergic reaction to any of the three active ingredients. And because it contains a long-acting bronchodilator, it should never be used alongside another long-acting bronchodilator inhaler, as doubling up increases the risk of serious cardiovascular side effects like rapid heart rate.
People with certain pre-existing conditions, including narrow-angle glaucoma or urinary retention, should discuss these with their prescriber before starting, since the anticholinergic component can worsen both.